We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals

125 hedge funds and large institutions have $444M invested in Kiniksa Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 8

156% more call options, than puts

Call options by funds: $6.89M | Put options by funds: $2.69M

20% more funds holding

Funds holding: 104125 (+21)

17% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 35

16% more capital invested

Capital invested by funds: $383M → $444M (+$61M)

0.51% more ownership

Funds ownership: 86.8%87.31% (+0.51%)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
125
Holders Change
+21
Holders Change %
+20.19%
% of All Funds
2.01%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
30
Increased
41
Reduced
35
Closed
8
Calls
$6.89M
Puts
$2.69M
Net Calls
+$4.2M
Net Calls Change
+$1.31M
Name Holding Trade Value Shares
Change
Change in
Stake
UOC
126
UBS O'Connor
Illinois
-$1.81M -140,962 Closed
JF
127
Jump Financial
Illinois
-$249K -19,400 Closed
XT
128
XTX Topco
Cayman Islands
-$216K -16,807 Closed
Walleye Trading
129
Walleye Trading
New York
-$202K -15,763 Closed
Jane Street
130
Jane Street
New York
-$144K -11,194 Closed
Teacher Retirement System of Texas
131
Teacher Retirement System of Texas
Texas
-$130K -10,105 Closed
Macquarie Group
132
Macquarie Group
Australia
-$56K -4,020 Closed
PHK
133
Point72 Hong Kong
Hong Kong
-$4K -350 Closed

KNSA Hedge Fund Activity: Q4 2022 in Review

125 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2022, worth a combined $444M — up 16% from $383M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new KNSA positions and 8 closed out — a net gain of 22 holders — while 41 added to existing stakes and 35 trimmed.

The largest buyer was State Street, adding an estimated $12.8M. The largest seller was Pictet Asset Management (Switzerland), cutting an estimated $26.3M.

  • 125 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2022, up from 104 in Q3 2022.
  • Funds reported $444M of Kiniksa Pharmaceuticals stock for Q4 2022, up 16% quarter-over-quarter.
  • 30 funds opened new Kiniksa Pharmaceuticals positions in Q4 2022 and 8 closed out, a net change of +22 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q4 2022 was State Street, an estimated $12.8M added.
  • The largest Kiniksa Pharmaceuticals seller in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $26.3M sold.

Based on aggregated 13F filings for Q4 2022.